Green tea cuts obesity, health risks in mice

Green tea cut obesity and a number of inflammatory biomarkers linked with poor health in a new study. Mice fed a diet of 2 percent green tea extract fared far better than those that ate a diet without it, a finding that has prompted an upcoming study of green tea's potential benefits in people at high risk of diabetes and heart disease.

The benefits seen in the new study, published in the Journal of Nutritional Biochemistry, appear to stem from improved gut health, including more beneficial microbes in the intestines of the mice and less permeability in the intestinal wall - a condition typically called "leaky gut" in people.

"This study provides evidence that green tea encourages the growth of good gut bacteria, and that leads to a series of benefits that significantly lower the risk of obesity," said Richard Bruno, the study's lead author and a professor of human nutrition at The Ohio State University.

Negative changes in the gut microbiome have been previously linked to obesity, and green tea has been shown to promote healthy bacteria. The Ohio State team wanted to explore whether there was an argument for green tea preventing obesity, inflammation and other factors connected to poor metabolic health, said Bruno, who is also a member of the Ohio Agricultural Research and Development Center.

"The results of studies looking at obesity management so far have been a real mixed bag. Some seem to support green tea for weight loss, but a lot of other research has shown no effect, likely due to the complexity of the diet relative to a number of lifestyle factors. Our goal is to figure out how it prevents weight gain," he said. "This will lead to better health recommendations."

Green tea has a rich history in Asian countries and has been increasingly embraced in the West, in part for its potential health benefits. Catechins, anti-inflammatory polyphenols found in green tea, have been linked to anti-cancer activity and lower risk of heart and liver disease.

Bruno and his colleagues suspected that green tea might prevent obesity and protect against inflammation in the gut based on previous studies, so they devised an experiment that examined green tea's effects in male mice fed a normal diet and a high-fat diet designed to cause obesity. (Female mice are resistant to diet-induced obesity and insulin resistance, a precursor to diabetes, so they weren't included.)

For eight weeks, half of the animals ate a high-fat diet designed to lead to obesity and half were fed a regular diet. In each of those groups, half ate green tea extract mixed in with their food.

Then the researchers measured body and fat tissue weight, insulin resistance and other factors that included:

  • Gut permeability, or how 'leaky' the gut was
  • Endotoxin translocation, or the movement of a gut bacteria-derived component to the bloodstream, where it provokes inflammation and insulin resistance
  • Inflammation in the fat tissue and intestines
  • The composition of the gut microbes, which are known to contribute to a variety of health factors

The mice fed a high-fat diet supplemented with green tea gained about 20 percent less weight and had lower insulin resistance than mice fed an otherwise identical diet without tea.

Those mice also had less inflammation within fat tissue and the intestine. Furthermore, the green tea appeared to protect against the movement of endotoxin, the toxic bacterial component, out of their guts and into the bloodstream.

Plus, the researchers found evidence of stronger - less "leaky" - guts in these mice. Leaky gut is a problem in humans that contributes to widespread low-grade inflammation and has been implicated in a number of health problems.

The researchers also found that the green tea appeared to contribute to a healthier microbial community in the guts of the mice fed a high-fat diet. Mice fed the normal, or low-fat, diet supplemented with green tea also had benefits including reduced weight gain and lower endotoxin levels and markers of leaky gut, but these were relatively modest compared with the effects seen in mice fed the high-fat diet.

Green tea consumption in the experiment would be equivalent to about 10 cups of green tea throughout the day for a person, Bruno said.

"It might seem like a lot of tea, but it's not highly unusual in certain parts of the world," he said.

Bruno is currently working on a human study that will explore the effects of green tea on leaky gut in people with metabolic syndrome - a condition that predisposes people to Type 2 diabetes and heart disease.

For now, he said, it's too soon to extrapolate the findings in animals to people. He also cautioned that - should the benefits prove true in humans - green tea supplements would not be an obvious substitute for drinking the beverage over the course of a day, because of how the body metabolizes the catechins in the tea.

"Consuming a little throughout the course of a day with food - like the mice did in this study - might be better," Bruno said.

He said he's hopeful that future research will determine whether drinking green tea might be a good strategy for those looking to reduce their chances of becoming obese.

"Two-thirds of American adults are overweight or obese, and we know that just telling people to eat less and exercise more isn't working. It's important to establish complementary health-promoting approaches that can prevent obesity and related problems," Bruno said.

Eunhee Chunga, Salvatore N Campisea, Hayli E.Joiner, Michael D Tomison, Gurvinder Kaur, Jannette M Dufour, Lillian Cole, Latha Ramalingam, Naima Moustaid-Moussa, Chwan-Li Shen.
Effect of annatto-extracted tocotrienols and green tea polyphenols on glucose homeostasis and skeletal muscle metabolism in obese male mice.
The Journal of Nutritional Biochemistry, Volume 67, May 2019, Pages 36-43. doi: 10.1016/j.jnutbio.2019.01.021.

Most Popular Now

Bayer Thrombosis Research Award 2019 goes to Dr. C…

The fourth winner of the Bayer Thrombosis Research Award has been chosen. The Scientific Committee of the Bayer Science & Education Foundation awarded the EUR 30,000 priz...

Roche enters into definitive merger agreement to a…

Roche (SIX: RO, ROG; OTCQX: RHHBY) and Spark Therapeutics, Inc. (NASDAQ: ONCE) have entered into a definitive merger agreement for Roche to fully acquire Spark Therapeuti...

Brilinta’s Phase III THEMIS trial met primary endp…

The Phase III THEMIS trial met its primary endpoint and demonstrated that Brilinta (ticagrelor), taken in conjunction with aspirin, showed a statistically-significant red...

Jury upholds Amgen's patents on Repatha® (evolocum…

Amgen (NASDAQ:AMGN) announced that a Delaware jury delivered a verdict in Amgen's favor upholding the validity of two Amgen patents related to PCSK9 antibodies. These pat...

Protein content as a marker for response to therap…

Brain tumors vary widely in how they respond to treatment. However, early assessment of therapy response is essential in order to choose the best possible treatment for t...

Artificial lung cancer tissue could help find new …

A 3D hydrogel created by researchers in U of T Engineering Professor Molly Shoichet's lab is helping University of Ottawa researchers to quickly screen hundreds of potent...

Could medical marijuana help grandma and grandpa w…

Medical marijuana may bring relief to older people who have symptoms like pain, sleep disorders or anxiety due to chronic conditions including amyotrophic lateral scleros...

New treatment offers potentially promising results…

A pioneering clinical trials program that delivered an experimental treatment directly to the brain offers hope that it may be possible to restore the cells damaged in Pa...

Amgen, Cytokinetics and Servier announce start of …

Amgen (NASDAQ: AMGN), Cytokinetics, Incorporated (NASDAQ: CYTK) and Servier today announced that METEORIC-HF (Multicenter Exercise Tolerance Evaluation of Omecamtiv Mecar...

Could blockchain ensure integrity of clinical tria…

UC San Francisco researchers have created a proof-of-concept method for ensuring the integrity of clinical trials data with blockchain. The system creates an immutable au...

Novartis data confirm rapid response and high effi…

Novartis announced today new data in 441 Chinese patients with moderate to severe plaque psoriasis from a Phase III study investigating the efficacy and safety of Cosenty...

Abbott and Novo Nordisk enter partnership to provi…

Abbott and Novo Nordisk today announced a non-exclusive partnership that will integrate insulin dose data from Novo Nordisk pre-filled and durable connected pens directly...